Unlike third-generation EGFR-TKI, MET amplification is less common, which has been only reported in less than 5% of EGFR-mutated NSCLC patients with acquired resistance to first- and second-generation EGFR TKIs. The gene discussed is MET; the disease is non-small cell lung carcinoma.